Understanding the Differences Between Digital and Traditional Biomarkers

Introduction: The Evolving Landscape of Biomarker Development

Biomarkers are critical in modern clinical development, serving as indicators of disease progression, treatment response, and patient outcomes. Historically, biomarkers have been derived from blood tests, imaging, or biopsies—requiring in-clinic visits and often invasive collection. However, with advances in wearable technology, digital biomarkers have emerged as a powerful complement, offering real-time, continuous insights into physiological and behavioral metrics.

This article compares digital biomarkers with traditional ones across domains like data capture, validation, regulatory acceptance, and clinical utility—helping sponsors and CROs select the best tool for each trial objective.

Definition and Scope: Traditional vs Digital Biomarkers

The FDA defines biomarkers as “characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or responses to an exposure or intervention.” Based on this, we can distinguish:

• Traditional Biomarkers: Derived from biological samples (e.g., plasma CRP, serum creatinine), imaging (MRI lesion count), or clinical assessments (e.g., MMSE score)
• Digital Biomarkers: Derived from data captured through digital tools such as wearables, apps, sensors, or connected devices (e.g., gait speed from accelerometer, HRV from PPG sensor)

Both must meet similar standards of analytical validity, clinical validity, and contextual relevance to be used in trials.

Data Capture Characteristics

A fundamental difference lies in how and when data is collected:

Digital biomarkers enhance patient comfort and reduce site burden but may introduce challenges in signal fidelity and standardization.

Analytical and Clinical Validation

Both types of biomarkers must meet rigorous validation criteria:

• Analytical Validity: Does the measurement accurately and reliably reflect the intended metric?
• Clinical Validity: Does the biomarker correlate with clinical outcomes or disease states?
• Clinical Utility: Does the biomarker meaningfully influence patient management or trial decisions?

Traditional biomarkers benefit from decades of assay optimization and published standards. In contrast, digital biomarkers may use proprietary algorithms that require bespoke validation. For example, gait speed from a smartphone accelerometer must be benchmarked against stopwatch-timed tests to establish equivalence.

Regulatory Acceptance and Qualification

Regulatory bodies like the FDA and EMA have biomarker qualification programs. However, digital biomarkers are still in the early phases of widespread acceptance:

• Traditional Biomarkers: Several are FDA-qualified (e.g., KIM-1 for kidney injury)
• Digital Biomarkers: Most are accepted as exploratory or secondary endpoints, with few approved as primary endpoints

The Digital Health Center of Excellence (FDA) and EMA Innovation Task Force are accelerating digital endpoint evaluation, especially for neurodegenerative and cardiology trials.

Comparative Advantages and Limitations

Both biomarker types have specific strengths and trade-offs. Selection should align with the trial’s objectives, therapeutic area, and feasibility constraints.

Real-World Case Examples

Example 1: Parkinson’s Disease
– Traditional Biomarker: UPDRS (clinician-rated scale)
– Digital Biomarker: Wrist-based tremor amplitude via accelerometer
Advantage: Tremor frequency captured 24/7 vs clinic-only subjective scale

Example 2: Heart Failure
– Traditional Biomarker: NT-proBNP from blood
– Digital Biomarker: Respiratory rate and thoracic impedance from a smart patch
Advantage: Early detection of decompensation trends through passive tracking

For additional wearable biomarker validation examples, visit PharmaValidation.

Use in Endpoint Hierarchies

In many trials, digital and traditional biomarkers are not mutually exclusive. They can complement each other in endpoint hierarchies:

• Primary Endpoint: Established biomarker with proven clinical relevance
• Secondary Endpoint: Novel digital biomarker supporting exploratory analysis
• Safety Signals: Passive wearable data can identify adverse trends in real time

For instance, a COPD trial may use FEV1 as the primary endpoint and use cough frequency via mobile microphone as a secondary measure.

Challenges in Harmonizing Data

Integrating digital biomarkers with traditional lab or imaging data poses challenges:

• Differences in units and sampling rates
• Data quality and missingness in wearables
• Synchronizing timestamped events across platforms
• Maintaining consistency across global sites with varying tech access

CROs should ensure SOPs for data standardization, alignment to CDISC formats, and proper source data verification (SDV) for digital endpoints.

Future Outlook: Bridging the Divide

With the growth of real-world evidence and decentralized trials, digital biomarkers are gaining traction. However, traditional biomarkers still form the foundation of regulatory submission and medical decision-making.

Emerging trends include:

• Hybrid biomarkers (e.g., combining HRV + inflammatory protein levels)
• AI-enabled interpretation of combined biosignals
• Cloud-native biomarker platforms with validated analytics pipelines

Conclusion: Integrating Strengths for Better Trials

The future of clinical trials lies in harmonizing the precision of traditional biomarkers with the contextual richness of digital ones. When deployed appropriately, digital biomarkers offer enhanced temporal resolution, patient-centricity, and decentralized feasibility—making trials more efficient and meaningful.

Sponsors and CROs should pursue validation, interoperability, and regulatory engagement to integrate digital endpoints as standard tools in the clinical development toolkit.